Literature DB >> 30849371

VEGF in Signaling and Disease: Beyond Discovery and Development.

Rajendra S Apte1, Daniel S Chen2, Napoleone Ferrara3.   

Abstract

The discovery of vascular endothelial-derived growth factor (VEGF) has revolutionized our understanding of vasculogenesis and angiogenesis during development and physiological homeostasis. Over a short span of two decades, our understanding of the molecular mechanisms by which VEGF coordinates neurovascular homeostasis has become more sophisticated. The central role of VEGF in the pathogenesis of diverse cancers and blinding eye diseases has also become evident. Elucidation of the molecular regulation of VEGF and the transformative development of multiple therapeutic pathways targeting VEGF directly or indirectly is a powerful case study of how fundamental research can guide innovation and translation. It is also an elegant example of how agnostic discovery and can transform our understanding of human disease. This review will highlight critical nodal points in VEGF biology, including recent developments in immunotherapy for cancer and multitarget approaches in neovascular eye disease.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30849371      PMCID: PMC6410740          DOI: 10.1016/j.cell.2019.01.021

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  203 in total

Review 1.  Neovascularization in retinopathy of prematurity: opposing actions of neuronal factors GPR91 and semaphorins 3A.

Authors:  Jean-Sébastien Joyal; Samy Omri; Nicholas Sitaras; José-Carlos Rivera; Przemyslaw Sapieha; Sylvain Chemtob
Journal:  Acta Paediatr       Date:  2012-05-05       Impact factor: 2.299

Review 2.  VEGF as a mediator of tumor-associated immunodeficiency.

Authors:  J E Ohm; D P Carbone
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 3.  From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease.

Authors:  Christian Caprara; Christian Grimm
Journal:  Prog Retin Eye Res       Date:  2011-11-16       Impact factor: 21.198

4.  Vascular endothelial growth factor is a secreted angiogenic mitogen.

Authors:  D W Leung; G Cachianes; W J Kuang; D V Goeddel; N Ferrara
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

Review 5.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.

Authors:  Dai Fukumura; Jonas Kloepper; Zohreh Amoozgar; Dan G Duda; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2018-03-06       Impact factor: 66.675

6.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

7.  Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.

Authors:  Kimberly E Stepien; Philip J Rosenfeld; Carmen A Puliafito; William Feuer; Wei Shi; Luma Al-Attar; Sander R Dubovy; Timothy G Murray; Janet L Davis; Wen-Hsiang Lee; Stephen G Schwartz; William E Smiddy; Audina M Berrocal; Harry W Flynn
Journal:  Retina       Date:  2009-09       Impact factor: 4.256

8.  Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.

Authors:  Megan M Geloneck; Alice Z Chuang; W Lloyd Clark; Michael G Hunt; Alan A Norman; Eric A Packwood; Khaled A Tawansy; Helen A Mintz-Hittner
Journal:  JAMA Ophthalmol       Date:  2014-11       Impact factor: 7.389

9.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

10.  VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread.

Authors:  Xiujuan Li; Narendra Padhan; Elisabet O Sjöström; Francis P Roche; Chiara Testini; Naoki Honkura; Miguel Sáinz-Jaspeado; Emma Gordon; Katie Bentley; Andrew Philippides; Vladimir Tolmachev; Elisabetta Dejana; Radu V Stan; Dietmar Vestweber; Kurt Ballmer-Hofer; Christer Betsholtz; Kristian Pietras; Leif Jansson; Lena Claesson-Welsh
Journal:  Nat Commun       Date:  2016-03-23       Impact factor: 14.919

View more
  404 in total

1.  Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer.

Authors:  Martin Pichler; Cristian Rodriguez-Aguayo; Su Youn Nam; Mihnea Paul Dragomir; Recep Bayraktar; Simone Anfossi; Erik Knutsen; Cristina Ivan; Enrique Fuentes-Mattei; Sang Kil Lee; Hui Ling; Tina Catela Ivkovic; Guoliang Huang; Li Huang; Yoshinaga Okugawa; Hiroyuki Katayama; Ayumu Taguchi; Emine Bayraktar; Rajat Bhattacharya; Paola Amero; William Ruixian He; Anh M Tran; Petra Vychytilova-Faltejskova; Christiane Klec; Diana L Bonilla; Xinna Zhang; Sanja Kapitanovic; Bozo Loncar; Roberta Gafà; Zhihui Wang; Vittorio Cristini; Samir M Hanash; Menashe Bar-Eli; Giovanni Lanza; Ondrej Slaby; Ajay Goel; Isidore Rigoutsos; Gabriel Lopez-Berestein; George Adrian Calin
Journal:  Gut       Date:  2020-01-27       Impact factor: 23.059

Review 2.  The role of inflammation in diabetic eye disease.

Authors:  Marina Mesquida; Faye Drawnel; Sascha Fauser
Journal:  Semin Immunopathol       Date:  2019-06-07       Impact factor: 9.623

Review 3.  Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication.

Authors:  Jan-Bernd Funcke; Philipp E Scherer
Journal:  J Lipid Res       Date:  2019-06-17       Impact factor: 5.922

4.  FGF2-induced STAT3 activation regulates pathologic neovascularization.

Authors:  Zhenyu Dong; Andrea Santeford; Norimitsu Ban; Tae Jun Lee; Craig Smith; David M Ornitz; Rajendra S Apte
Journal:  Exp Eye Res       Date:  2019-08-23       Impact factor: 3.467

Review 5.  Decoding leader cells in collective cancer invasion.

Authors:  Samuel A Vilchez Mercedes; Federico Bocci; Herbert Levine; José N Onuchic; Mohit Kumar Jolly; Pak Kin Wong
Journal:  Nat Rev Cancer       Date:  2021-07-08       Impact factor: 60.716

6.  Engineered human myocardium with local release of angiogenic proteins improves vascularization and cardiac function in injured rat hearts.

Authors:  Fabiola Munarin; Rajeev J Kant; Cassady E Rupert; Amelia Khoo; Kareen L K Coulombe
Journal:  Biomaterials       Date:  2020-04-12       Impact factor: 12.479

7.  TPTEP1 suppresses high glucose-induced dysfunction in retinal vascular endothelial cells by interacting with STAT3 and targeting VEGFA.

Authors:  Xiaoping Sun; Yuebing Lu; Tao Lei
Journal:  Acta Diabetol       Date:  2021-02-12       Impact factor: 4.280

Review 8.  VEGF-A and blood vessels: a beta cell perspective.

Authors:  Willem Staels; Yves Heremans; Harry Heimberg; Nico De Leu
Journal:  Diabetologia       Date:  2019-08-14       Impact factor: 10.122

9.  Ovarian Cancer Stem Cells: Characterization and Role in Tumorigenesis.

Authors:  Sarama Saha; Seema Parte; Partha Roy; Sham S Kakar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  An inhibitor of endothelial ETS transcription factors promotes physiologic and therapeutic vessel regression.

Authors:  Christopher M Schafer; Jami M Gurley; Katarzyna Kurylowicz; Prisca K Lin; Wen Chen; Michael H Elliott; George E Davis; Faizah Bhatti; Courtney T Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.